Fact sheet: AXA Framlington Biotech

Fund information

Fund name
AXA Framlington Biotech Z Acc
Fund company manager
AXA IM UK
Fund type
UKA
Fund manager
Deane Donnigan
since 01/09/2007
Fund objective
The aim of this Fund is to provide long-term capital growth.
Benchmark
NASDAQ Biotechnology
Investment style
Growth
Investment method
Shares

Performance snapshot

Quick stats

1 Year return

42.93 %

1 Year rank in sector

5/106

Sector

UT Specialist

Yield
-
Fund size

£ 541.5 m

FE Risk score

209

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    83.39%
  • UK
    3.75%
  • France
    3.03%
  • Sweden
    3.01%
  • Money Market
    2.66%
  • Biotechnology/Medical
    74.93%
  • Pharmaceuticals
    15.42%
  • Technology
    4.16%
  • Money Market
    2.66%
  • Electronic & Electrical Equipment
    2.03%
  • US Equities
    83.39%
  • UK Equities
    3.75%
  • French Equities
    3.03%
  • Swedish Equities
    3.01%
  • Money Market
    2.66%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund11.06 %15.01 %42.93 %65.44 %205.01 %
Sector0.51 %5.85 %18.47 %19.77 %38.19 %
Rank within sector1 / 1089 / 1065 / 1065 / 991 / 84
Quartile th1 st1 st1 st1 st1 st

Calendar performance

YTD-20172016201520142013
Fund13.9 %-4.95 %12.29 %46.68 %65.24 %
Sector4.25 %22.72 %-4.47 %1.15 %4.5 %
Rank within sector7 / 106105 / 1054 / 1014 / 971 / 87
Quartile th1 st4 th1 st1 st1 st

Risk statistics

Alpha11.3
Beta0.82
Sharpe0.47
Volatility24.27
Tracking error22.94
Information ratio0.31
R-Squared0.11

Price movement

52 week high330.3
52 week low229.8
Current bid price0
Current offer price0
Current mid price330.3

Holdings by region

  • 83.39% USA
  • 3.75% UK
  • 3.03% France
  • 3.01% Sweden
  • 2.66% Money Market
  • 2.59% Belgium
  • 0.78% Switzerland
  • 0.4% Germany
  • 0.39% Canada

Holdings by sector

  • 74.93% Biotechnology/Medical
  • 15.42% Pharmaceuticals
  • 4.16% Technology
  • 2.66% Money Market
  • 2.03% Electronic & Electrical Equipment
  • 0.81% Health Care

Holdings by asset type

  • 83.39% US Equities
  • 3.75% UK Equities
  • 3.03% French Equities
  • 3.01% Swedish Equities
  • 2.66% Money Market
  • 2.59% Belgian Equities
  • 0.78% Swiss Equities
  • 0.4% German Equities
  • 0.39% Canadian Equities

Individual holdings

  • 9.2% CELGENE CORP
  • 8.1% BIOGEN INC
  • 8.1% GILEAD SCIENCES INC
  • 6.6% ALEXION PHARMACEUTICALS INC
  • 4.7% AMGEN INC
  • 4.2% REGENERON PHARMACEUTICALS INC
  • 4.1% ILLUMINA INC
  • 4% BIOMARIN PHARMACEUTICAL
  • 3.3% INCYTE CORP
  • 2.9% VERTEX PHARMACEUTICAL